Major drug interactions
This medicine may have important interactions with other medicines.
Leaflet EPTIFIBATIDA MYLAN 0.75mg / ml solution for infusion
- Product code:
- W63136001
- Quantity:
- 1
- Indicated for:
- prevention of atherothrombotic events
- Route of administration:
- infusion
- Substance:
- eptifibatide (antiplatelet agent)
- ATC
- B01AC16 — Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin
Precautions:
Bleeding risk
This medicine may increase the risk of bleeding.
Eptifibatide is an antiplatelet medication used to prevent blood clot formation in patients with acute coronary syndromes or those undergoing coronary angioplasty procedures. It works by inhibiting platelet aggregation, thus reducing the risk of myocardial infarction or other cardiovascular complications.
Eptifibatide is administered intravenously under strict medical supervision, usually in a hospital setting, before, during, or after cardiac procedures. The dose is adjusted according to the patient's weight and the doctor's instructions.
Side effects may include bleeding, decreased platelet count, allergic reactions, or, rarely, hypotension. Careful monitoring of blood parameters is essential during treatment.
Eptifibatide is an effective option for reducing the risk of thrombotic complications in patients with heart conditions, but its use requires specialized medical supervision.
Eptifibatide is administered intravenously under strict medical supervision, usually in a hospital setting, before, during, or after cardiac procedures. The dose is adjusted according to the patient's weight and the doctor's instructions.
Side effects may include bleeding, decreased platelet count, allergic reactions, or, rarely, hypotension. Careful monitoring of blood parameters is essential during treatment.
Eptifibatide is an effective option for reducing the risk of thrombotic complications in patients with heart conditions, but its use requires specialized medical supervision.
General data about EPTIFIBATIDA MYLAN 0.75mg / ml
- Substance:
- eptifibatide
- Date of latest medicines list:
- 01-03-2017
- Product code:
- W63136001
- Concentration:
- 0.75mg / ml
- Pharmaceutical form:
- solution for infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for eptifibatide
Concentrations available for eptifibatide
- 0.75mg/ml
- 2mg/ml